Probability of success in phase II dominates the drug development cost calculus, with phase I/II as the critical juncture for proof of concept. Failure to address fundamental pharmacologic questions in early development is alarmingly frequent and a strong predictor of failure. Safety, manufacture, formulation, and commercialization issues are also vital. Systems biology provides a framework to analyze genomic, proteomic, and metabolomic data and construct complex network models of molecular pathophysiology. Biomarkers offer the largest learning opportunity, and combined adaptive protocol designs provide a lean but scientifically robust path to proof of concept. The traditional model of phase I study execution in a clinical pharmacology unit is evolving to a networked model of an integrated early clinical development platform. The power of this platform is enhanced with a proactive multidisciplinary approach to quality and safety, including lean 6 sigma tools and simulations.
Abrantes-MetzRAdamsCMetzA. Pharmaceutical development phases: a duration analysis. Washington, DC: Bureau of Economics; 2004. Working paper 274. http://www.ftc.gov/be/workpapers/wp274.pdf.
2.
HayMThomasDWCraigheadJLEconomidesCRosenthalJ. Clinical development success rates for investigational drugs. Nat Biotechnol. 2014;32:40–51.
3.
DouglasFLNarayananVKMitchellLLitanRE. The case for entrepreneurship in R&D in the pharmaceutical industry. Nat Rev Drug Discov. 2010;9:683–689.
4.
PaulSMMytelkaDSDunwiddieCT. How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat Rev Drug Discov. 2010;9:203–214.
5.
CartwrightMECohenSFleishakerJC. Proof of concept: a PhRMA position paper with recommendations for best practice. Clin Pharmacol Ther. 2010;87:278–285.
6.
SheinerLB. Learning versus confirming in clinical drug development. Clin Pharmacol Ther. 1997;61:275–291.
7.
DethloffL.Strategies to reduce compound attrition in early development. Paper presented at: CHI’s Accelerating Proof of Concept Conference; October 5, 2011; Philadelphia, PA.
8.
SwinneyDCAnthonyJ. How were medicines discovered?Nat Rev Drug Discov. 2011;10:507–179.
9.
DiMasiJAFeldmanLSecklerAWilsonA. Trends in risks associated with new drug development: success rates for investigational drugs. Clin Pharmacol Ther. 2010;87:272–277.
10.
SofatRHingoraniADSmeethL. Separating the mechanism-based and off-target actions of CETP-inhibitors using CETP gene polymorphisms. Circulation. 2010;121:52–62.
11.
VergeerMBotsMLvan LeuvenSI. Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials. Circulation. 2008;118:2515–2122.
12.
HayesE. Dalcetrapib failure raises yet more questions on value of tinkering with HDL cholesterol. Pink Sheet. 2012;74(20).
13.
MatthewsLBerryATersigniMD’AcquistoFIanaroARayD. Thiazolidinediones are partial agonists for the glucocorticoid receptor. Endocrinology. 2009;150:75–86.
ClaretLLuJFBrunoRHsuCPHeiYJSunYN. Simulations using a drug-disease modeling framework and phase II data predict phase III survival outcome in first-line non-small-cell lung cancer. Clin Pharmacol Ther. 2012;92:631–634.
23.
BorrillZLHoughtonCMTal-SingerR. The use of plethysmography and oscillometry to compare long-acting bronchodilators in patients with COPD. Br J Clin Pharmacol. 2008;65:244–252.
24.
DiamantZTarasevychSClarkeGW. New and existing pharmacotherapeutic options for persistent asthma and COPD. Neth J Med. 2011;69:486–499.
25.
DiamantZClarkeGWPieterseHGispertJ. Disease models of chronic inflammatory airway disease: applications and requirements for clinical trials. Curr Opinion Pulm Med. 2014;20:37–45.
26.
van KuijkAWRGerlagDMVosK. A prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tissue. Ann Rheum Dis. 2009;68:1303–1309.
27.
SuntharalingamGPerryMRWardS. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 2006;355:1018–1028.
28.
SoRelleR. Human gene therapy: science under fire. Circulation. 2000;101:e9023–e9024.
29.
SavulescuJSpriggsM. The Hexamethonium Asthma Study and the death of a normal volunteer in research. J Med Ethics. 2002;28:3–4.
